Group 1 - The company announced that it will not adjust the conversion price of the "Shou 22 Convertible Bond" downward during the next six months, from September 16, 2025, to March 15, 2026 [1] - If the downward adjustment clause is triggered again, the board will hold another meeting to decide whether to exercise the right to adjust the conversion price [1] - The first trading day for recalculating the conversion price will be March 16, 2026, or the next trading day if it falls on a non-trading day [1]

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2025-059 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于不向下修正"寿 22 转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 自 2025 年 8 月 26 日至 2025 年 9 月 15 日期间，浙江寿仙谷医药股份有 限公司（以下简称"公司"、"寿仙谷"）股票满足连续三十个交易日中有十五个交 易日的收盘价低于"寿 22 转债"当期转股价格的 85%（即 31.31 元/股），已触发 "寿 22 转债"转股价格向下修正条款。 经公司第五届董事会第三次会议审议通过，决定本次不向下修正"寿 22 转债"转股价格，且未来六个月内（2025 年 9 月 16 日至 2026 年 3 月 15 日）， 若再次触发"寿 22 转债"转股价格向下修正条款，亦不提出向下修正方案。以 2026 年 3 月 16 日（若为 ...

Investment Rating - The industry rating is maintained at "Overweight" [7] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 0.03% last week, while the overall pharmaceutical sector experienced a minor decline of 0.36% [2] - The TCM sector's PE (ttm) is at 28.52X, with a PB (lf) of 2.42X, indicating a stable valuation compared to historical data [3] - The demand for TCM materials is expected to rise as the traditional medication peak season approaches, leading to a rebound in market conditions [4] - The promotion of TCM at the grassroots level is anticipated to accelerate, supported by government initiatives to enhance TCM services in community health centers and county hospitals [5][6] Market Performance - The TCM sector's index closed at 6720.55 points, reflecting a 0.03% increase, while the pharmaceutical sector index was at 9157.77 points, down 0.36% [2][18] - The performance of individual companies within the TCM sector varied, with leading companies including Yiling Pharmaceutical and Wanbangde, while companies like Kangyuan Pharmaceutical and Zhendong Pharmaceutical lagged [2][15][17] Valuation - The TCM sector's PE (ttm) is at 28.52X, unchanged from the previous week, with a one-year maximum of 30.26X and a minimum of 22.58X [3] - The PB (lf) stands at 2.42X, also stable, with a one-year maximum of 2.65X and a minimum of 1.99X [3] Policy and Regulatory Environment - The State Council's recent approval of the "Healthcare Strengthening Foundation Project" aims to enhance the use of TCM in grassroots healthcare settings, which is expected to significantly impact the sector [5] - The National Health Commission's response regarding the basic drug directory management indicates potential adjustments that could favor TCM applications in grassroots markets [6] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [10][11] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and leading TCM brands [10][11]

Core Viewpoint - The company has faced continuous pressure on its performance and stock price, with investors questioning the feasibility of its ambitious sales targets in light of recent declines in revenue and profit [1] Group 1: Financial Performance - The company has averaged annual sales of approximately 700 million yuan in recent years, with a significant drop in revenue and net profit in the first half of 2023, down 16.51% and 33.99% respectively [1] - The company set a vision to achieve 10 billion yuan in revenue by 2035, but has struggled since 2019, with 2022 revenue peaking at 829 million yuan [1] Group 2: Marketing Strategy - The company has faced criticism for its conservative marketing strategy, which is believed to have negatively impacted product market performance [2] - In response, the company has shifted its strategic focus to "marketing-driven enterprise" and is implementing marketing reforms, including enhancing offline channels and exploring new retail avenues [2] - The company has begun to engage in live-streaming sales, partnering with top live-streaming teams to boost online marketing efforts [2]

Group 1 - The company announced that from August 26, 2025, to September 8, 2025, its stock price has been below 85% of the conversion price of "Shou 22 Convertible Bond" for ten consecutive trading days [1] - If the stock price remains below 85% of the conversion price for five trading days within the next twenty consecutive trading days, it will trigger the downward adjustment clause for the conversion price of "Shou 22 Convertible Bond" [1] - The company's board of directors has the authority to propose a downward adjustment plan for the conversion price, which will be submitted for shareholder approval according to the relevant provisions in the prospectus of the convertible bonds [1]

浙江寿仙谷医药股份有限公司 关于"寿 22 转债"预计满足转股价格向下修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 自 2025 年 8 月 26 日至 2025 年 9 月 8 日期间，浙江寿仙谷医药股份有限 公司（以下简称"公司"、"寿仙谷"）股票已连续十个交易日的收盘价格低于 "寿 22 转债"当期转股价 36.84 元/股的 85%（即 31.31 元/股），若在未来连续 二十个交易日内，公司股票有五个交易日的收盘价低于当期转股价格的 85%，将 触发"寿 22 转债"的转股价格向下修正条款。届时根据《寿仙谷公开发行可转 换公司债券募集说明书》（以下简称"《募集说明书》"）中转股价格向下修正 条款的相关约定，公司董事会有权提出"寿 22 转债"转股价格向下修正方案并 提交公司股东大会表决。敬请广大投资者关注公司后续公告，注意投资风险。 一、"寿 22 转债"发行上市情况 经中国证券监督管理委员会"证监许可[2022]2165 号"文核准，浙江寿仙谷 医药股份有限公司（以下简称" ...

Group 1 - The company will hold a half-year performance briefing on September 12, 2025, from 13:00 to 14:30 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will combine video recording with online interaction [4][6] - Investors can submit questions from September 5 to September 11, 2025, and the company will address common concerns during the briefing [2][6] Group 2 - Key participants in the briefing include the Chairman, General Manager, Secretary of the Board, Financial Officer, and Independent Directors [5] - Investors can participate online through the Shanghai Stock Exchange Roadshow Center during the scheduled time [6] - After the briefing, investors can view the main content and outcomes on the Shanghai Stock Exchange Roadshow Center website [7]

证券日报网讯9月4日晚间，寿仙谷（603896）发布公告称，公司计划于2025年9月12日举行2025年半年 度业绩说明会。 ...

证券代码：603896 证券简称：寿仙谷 公告编号：2025-057 一、说明会类型 本次投资者说明会以视频结合网络互动方式召开，公司将针对 2025 年半年 度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露 允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点及活动日程 （一）会议召开时间：2025 年 9 月 12 日（星期五）下午 13:00-14:30 （二）会议召开地点：上海证券交易所上证路演中心（网址： 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于召开 2025 年上半度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 9 月 12 日（星期五）下午 13:00-14:30 浙江寿仙谷医药股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划 ...

公司代码：603896 公司简称：寿仙谷 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 Zhejiang Shouxiangu Pharmaceutical Co., Ltd. （浙江省武义县壶山街道商城路 10 号） 2025 年第一次临时股东大会 会议资料 浙江寿仙谷医药股份有限公司 2025 年第一次临时股东大会会议资料 浙江寿仙谷医药股份有限公司 2025 年第一次临时股东大会会议议程 一、会议召集人：浙江寿仙谷医药股份有限公司董事会 二〇二五年九月十八日 浙江寿仙谷医药股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 | 年第一次临时股东大会会议议程 2 | | --- | --- | | 2025 | 年第一次临时股东大会会议须知 4 | | | 议案一：关于变更公司注册资本、取消监事会暨修订《公司章程》的议案 6 | | | 议案二：关于修订部分公司治理制度的议案 43 | 1 二、会议召开的日期、时间： 现场会议时间：2025 年 9 月 18 日 14:00 网络投票起止时间：自 2025 年 9 月 18 日至 2025 年 9 月 ...